cladaxxa 50 mg Žvýkací tableta
krka d.d. novo mesto - amoxicillin and beta-lactamase inhibitor - Žvýkací tableta - kombinace penicilinů, včetně. beta-laktamázy inhibitory - kočky, psi
cladaxxa 500 mg Žvýkací tableta
krka d.d. novo mesto - amoxicillin and beta-lactamase inhibitor - Žvýkací tableta - kombinace penicilinů, včetně. beta-laktamázy inhibitory - psi
nexpovio
stemline therapeutics b.v. - selinexor - mnohočetný myelom - antineoplastická činidla - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunologická vyšetření pro suidae - prasata (výkrm) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastická činidla - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
cylanic 500+125 mg tableta
livisto int'l, s.l. - amoxicillin and beta-lactamase inhibitor - tableta - kombinace penicilinů, včetně. beta-laktamázy inhibitory
cylanic 50+12,5 mg tableta
livisto int'l, s.l. - amoxicillin and beta-lactamase inhibitor - tableta - kombinace penicilinů, včetně. beta-laktamázy inhibitory - psi, kočky
cylanic 250+62,5 mg tableta
livisto int'l, s.l. - amoxicillin and beta-lactamase inhibitor - tableta - kombinace penicilinů, včetně. beta-laktamázy inhibitory - psi, kočky